Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.62 |
| ▸ | CES1 | P23141 | 4/20 | 0.62 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.59 |
| ▸ | PPARG | P37231 | 7/20 | 0.59 |
| ▸ | PPARD | Q03181 | 7/20 | 0.59 |
| ▸ | PPARA | Q07869 | 7/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.59 |
| ▸ | TSHR | P16473 | 5/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | TLR2 | O60603 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | FABP4 | P15090 | 2/20 | 0.59 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.59 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | PDE4A | P27815 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5510390 | 1.00 | CES2 (0.62) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL76015 | 1.00 | CES2 (0.62) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL217920 | 1.00 | CES2 (0.62) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL216281 | 1.00 | CES2 (0.62) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL42015 | 1.00 | CES2 (0.62) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL6755768 | 1.00 | CES2 (0.62) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL78734 | 1.00 | CES2 (0.62) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL217644 | 1.00 | CES2 (0.62) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL218241 | 1.00 | CES2 (0.62) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL502175 | 1.00 | CES2 (0.62) | CES2CES1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011070140-A2 | LUBRICATING OIL COMPOSITION | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2011-06-16 | — | — | WO | claimed |
| EP-1071702-A1 | FATTY ACID DERIVATIVES OF BILE ACIDS AND BILE ACID DERIVATIVES | Galmed International Ltd. (MT) | 2001-01-31 | — | — | EP | claimed |
| WO-1999052932-A1 | FATTY ACID DERIVATIVES OF BILE ACIDS AND BILE ACID DERIVATIVES | GALMED INTERNATIONAL LTD. (MT) | 1999-10-21 | — | — | WO | claimed |
| US-5679652-A | THERAPY FOR CANCER, INFECTIONS | SCHOTT HERBERT (DE) | 1997-10-21 | — | — | US | claimed |
| EP-0642527-B1 | AMPHIPHILIC NUCLEOSIDE PHOSPHATE ANALOGS | SCHOTT HERBERT (DE) | 1996-01-10 | — | — | EP | claimed |
| US-11166964-B2 | Treatment for modulating gut microbiota | GALMED RESEARCH AND DEVELOPMENT LTD (IL) | 2021-11-09 | — | — | US | disclosed |
| US-20210169901-A1 | TREATMENT FOR MODULATING GUT MICROBIOTA | GALMED RESEARCH AND DEVELOPMENT LTD. (IL) | 2021-06-10 | — | — | US | disclosed |
| CN-111233926-B | Thiamine compound, preparation method and pharmaceutical composition thereof | 上海日馨生物科技有限公司 | 2021-04-16 | — | — | CN | disclosed |
| CN-111233925-B | Thiamine compound, preparation method and pharmaceutical composition thereof | 上海日馨生物科技有限公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-111233926-A | Thiamine compound, preparation method and pharmaceutical composition thereof | 上海日馨生物科技有限公司 | 2020-06-05 | — | — | CN | disclosed |
| CN-111233925-A | Thiamine compound, preparation method and pharmaceutical composition thereof | 上海日馨生物科技有限公司 | 2020-06-05 | — | — | CN | disclosed |
| EP-3428202-A1 | PROCESS OF PRODUCING POLYOLEFINS USING METALLOCENE POLYMERIZATION CATALYSTS AND COPOLYMERS THEREFROM | ExxonMobil Chemical Patents Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-0648765-A1 | Process for the production of 3-arylbenzofuranones | CIBA-GEIGY AG (CH) | 1995-04-19 | — | — | EP | disclosed |
| EP-0644190-A1 | Benzofuran-2-ones as stabilizers | CIBA-GEIGY AG (CH) | 1995-03-22 | — | — | EP | disclosed |
| EP-0591102-A1 | 3-(2-Acyloxyethoxyphenyl)benzofuran-2-ones as stabilizers | CIBA-GEIGY AG (CH) | 1994-04-06 | — | — | EP | disclosed |
| EP-0589839-A1 | 3-(Dihydrobenzofuran-5-yl)benzofuran-2-ones as stabilizers | CIBA-GEIGY AG (CH) | 1994-03-30 | — | — | EP | disclosed |
| EP-0102319-B1 | PROPHYLACTIC AND THERAPEUTIC USE OF MURAMYL PEPTIDES AND THEIR ANALOGUES AGAINST VIRAL INFECTIONS | CIBA-GEIGY AG (CH) | 1987-08-19 | — | — | EP | disclosed |
| US-4436521-A | Process for producing dyed and anti-shrink treated wool | SANDOZ LTD. (CH) | 1984-03-13 | — | — | US | disclosed |
| EP-0102319-A1 | Prophylactic and therapeutic use of muramyl peptides and their analogues against viral infections | CIBA-GEIGY AG (CH) | 1984-03-07 | — | — | EP | disclosed |
| EP-0056992-A1 | Phosphorylated derivatives, pharmaceutical compositions containing such derivatives, and their use | CIBA-GEIGY AG (CH) | 1982-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210169901-A1 | TREATMENT FOR MODULATING GUT MICROBIOTA | NR1H4, SLC10A2, FABP2 | CES2 1593/4885CES1 55/4885GPR84 372/4885 |
| US-11166964-B2 | Treatment for modulating gut microbiota | NR1H4, SLC10A2, FABP2 | CES2 1593/4885CES1 55/4885GPR84 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.